Skip to content

A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose

A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05142358
Enrollment
8
Registered
2021-12-02
Start date
2022-10-19
Completion date
2026-01-28
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Sided Breast Cancer, Lung Cancer

Keywords

stereotactic body radiation therapy, continuous positive airway pressure, CPAP, radiation, cancer, lung, Deep inspiratory breath hold (DIBH)

Brief summary

Data collection and assessment on patients with left-sided breast cancer or undergoing lung stereotactic body radiation therapy (SBRT) utilizing continuous positive airway pressure (CPAP) devices.

Detailed description

Lung stereotactic body radiation therapy (SBRT) has emerged as a definitive treatment for patients with early-stage lung cancers as well as for patients with limited metastases to the lung. One challenge with the treatment of the lung is the risk of pulmonary toxicity, particularly for early-stage lungs cancers that are inoperable (those receiving primary lung SBRT) or those with metastatic cancers receiving systemic therapy that may impact pulmonary function (those receiving lung SBRT for metastatic cancers). Continuous positive airway pressure (CPAP) devices are commonly utilized for patients with obstructive sleep apnea. However, through the use of continuous pressure, lung volumes are increased. Preliminary data in patients undergoing breast radiation as well as lung radiation has demonstrated the safety and feasibility of such an approach, demonstrating increased lung volumes with decreases in heart dose6-8. Additional potential advantages of CPAP include increased ease of use for patients and the potential for cost savings as compared to traditional respiratory management techniques. This prospective study is to allow for the collection and assessment of data on patients with left-sided breast cancer or undergoing lung SBRT utilizing CPAP. This will allow for the assessment of lung doses with and without CPAP as well as cardiac doses. No additional changes to our standard of care breast or lung radiation will occur. With respect to the safety profile, CPAP is commonly used with limited toxicity concerns. The potential benefit of CPAP has reduced lung and heart doses and, consequently, radiation-related toxicities.

Interventions

DEVICEContinuous Positive Airway Pressure

Use of CPAP device at the start of treatment planning.

OTHERDeep inspiratory breath hold

Treatment during breath holds leads to longer treatment times for patients and radiation oncology departments

OTHERFree Breath

Regular breathing

Sponsors

Case Comprehensive Cancer Center
Lead SponsorOTHER
Varian Medical Systems
CollaboratorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

All participants will undergo standard of care radiation treatment. One additional CT scan will be performed with the use of a CPAP device to determine effect on dosimetry.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with left-sided breast cancers * Patients must be undergoing left breast/chest wall radiation with or without regional nodal irradiation * Patients undergoing lung SBRT * Primary lung cancers * Metastatic lung tumors

Exclusion criteria

* Patients with right side breast cancer * Patients who are unable to tolerate the CPAP device

Design outcomes

Primary

MeasureTime frameDescription
Dosimetry comparison CPAP and free breathing.At the time of Scan, " Day 1"The primary objective will be to assess changes in lung dosimetry V5 on the affected side when using CPAP compared to free breathing will be measured in percentages.

Secondary

MeasureTime frameDescription
Total Lung dosimetryAt the time of Scan, " Day 1"Total Lung dosimetry will be measured in Grays.
Cardiac dosimetry with CPAP as compared to free breathingAt the time of Scan, " Day 1"Cardiac dosimetry with CPAP as compared to free-breathing will be measured in Grays.
Measure breast/chest wall or lung tumor motion as well as organ at risk motionAt the time of Scan, " Day 1"Simulation scans will be performed with CPAP and free breathing. The breast/chest wall, and tumors (lung SBRT), as well as lung and heart, will be contoured on each scan. Using the CPAP scan as a reference, we will assess breast/chest wall motion, lung tumor motion, and organ at risk (ex. heart, abdominal organs) motion with free-breathing scans for each patient and analyze by treatment site (breast vs. lung SBRT).
Treatment time with CPAP treatmentsAt the time of Scan, " Day 1"Treatment time will be measured for each fraction
Confirm maintenance of inflation with CPAP using surface guidanceAt the time of Scan, " Day 1"At the time of simulation, investigators will create a surface rendering with the patient using CPAP. Investigators will assess maintenance of inflation when using CPAP where all three dimensions will be measured during treatment by comparing the surface rendering obtained during simulation with CPAP to the surface during treatment with CPAP, assessing for the greatest changes over the course of each fraction.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORSheeh Cherian, MD

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026